In order to achieve personalized cancer care, tools are needed to predict benefit from a specific therapy. Prostate cancer biomarker study is a key field to explore so that the natural course of a patient's disease can be predicted. A panel of inflammation/immune-related and prostate cancer-related genes was screened by Ross et al. to assess genes predictive of castration-resistant prostate cancer (CRPC) survival. They found that a six-gene model was superior to traditionally used clinic-pathological variables. Although the clinic utility of this model remains to be determined, the blood based technical achievement and potential may eventually improve personalized cancer care.

PDF | PDF |